LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial-Reference-Cited by-同舟云学术

LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

Published:2023-10 Issue: Volume:34 Page:S1306
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cho B.C.,Felip E.,Spira A.I.,Girard N.,Lee J-S.,Lee S-H.,Ostapenko Y.V.,Danchaivijitr P.,Liu B.,Alip A.,Korbenfeld E.P.,Dias J.,Sun T.,Martinez M.,Bauml J.M.,Shreeve M.,Sethi S.,Knoblauch R.E.,Hayashi H.,Lu S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer;Journal of Managed Care & Specialty Pharmacy;2024-09-11

2. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?;CLIN LUNG CANCER;2024

3. Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts;Cancer Research Communications;2024-09-01

4. Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer;Lung Cancer;2024-09

5. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development;Cancer Treatment Reviews;2024-09